Certara, Inc. (CERT)
| Market Cap | 3.81B |
| Revenue (ttm) | 275.40M |
| Net Income (ttm) | -58.01M |
| Shares Out | 159.68M |
| EPS (ttm) | -0.40 |
| PE Ratio | n/a |
| Forward PE | 111.11 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 386,165 |
| Open | 25.12 |
| Previous Close | 24.73 |
| Day's Range | 23.79 - 25.48 |
| 52-Week Range | 23.75 - 45.48 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 40.60 (+70.1%) |
| Earnings Date | n/a |
About CERT
Certara Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinincal and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software and technology to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, em...
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for Certara stock is "Buy." The 12-month stock price forecast is 40.60, which is an increase of 70.09% from the latest price.
News
Can Certara, Inc. (CERT) Run Higher on Rising Earnings Estimates?
Certara, Inc. (CERT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Can Certara, Inc. (CERT) Climb 35% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 35.1% in Certara, Inc. (CERT). While the effectiveness of this highly sought-after metric is questionable, the po...
Certara Announces FDA Renewal and Expansion of Certara's Biosimulation Software for Reviewing Regulatory Submissions
FDA holds more than 400 Simcyp™ and Phoenix™ software licenses across 12 divisions and offices FDA holds more than 400 Simcyp™ and Phoenix™ software licenses across 12 divisions and offices
Certara Announces Release of Pinnacle 21 Enterprise Software
New metrics and analytics capabilities enable informed decision making for biopharmaceutical clients New metrics and analytics capabilities enable informed decision making for biopharmaceutical clients
Certara to Host Investor Day on December 15, 2021
PRINCETON, N.J., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, will host an Investor Day on Wednesday, December 15, 2021 from 3:00 PM to 6:00 PM ET in...
Certara Announces Release of Simcyp™ Simulator Version 21, Expanding Capabilities to Align with Recent Regulatory Gui...
Simcyp Simulator has been used to inform more than 250 label claims for 85+ novel drugs Simcyp Simulator has been used to inform more than 250 label claims for 85+ novel drugs
Certara Announces Update of D360™ Scientific Informatics Software
New capabilities increase efficiency in analyzing and developing small molecules and biologic drugs New capabilities increase efficiency in analyzing and developing small molecules and biologic drugs
Certara Announces Closing of Public Offering of Common Stock
PRINCETON, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the closing of its underwritten public offering of 10,000,000 shares of...
Certara Announces Pricing of Public Offering of Common Stock
PRINCETON, N.J., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the pricing of its underwritten public offering of 10 million shares of...
Certara Announces Proposed Public Offering of Common Stock
PRINCETON, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced a proposed underwritten public offering by certain selling stockholders...
Certara Reports Third Quarter 2021 Financial Results
Raises full year 2021 guidance, reflecting strong revenue growth and the acquisition of Pinnacle 21 Raises full year 2021 guidance, reflecting strong revenue growth and the acquisition of Pinnacle 21
Certara Appoints James E. Cashman III as Chairman of Board of Directors
High-tech CEO with decades of experience supports continued innovation and growth High-tech CEO with decades of experience supports continued innovation and growth
Certara to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference
PRINCETON, N.J., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that William F. Feehery, Chief Executive Officer, and Andrew Schemick, ...
Pinnacle 21 Awarded FDA Contract for 5 Years for Software and Services
Pinnacle 21 Enterprise software expedites regulatory review of all study submission data Pinnacle 21 Enterprise software expedites regulatory review of all study submission data
Certara's Simcyp™ COVID-19 Vaccine Model Wins R&D 100 Award
Biosimulation tool to conduct ‘what-if' scenarios with virtual patients recognized in Software/Services category Biosimulation tool to conduct ‘what-if' scenarios with virtual patients recognized in Sof...
Certara to Report Third Quarter 2021 Financial Results on November 9th, 2021
PRINCETON, N.J., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2021 af...
Certara Appoints Patrick F. Smith to President of Integrated Drug Development
PRINCETON, N.J., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Patrick F. Smith, Pharm.D. as president of Integrate...
Certara Appoints Drayton T. Virkler as Chief Commercial Officer
Experienced commercial leader brings 20 years of experience in pharma Experienced commercial leader brings 20 years of experience in pharma
Certara Completes Acquisition of Pinnacle 21
Complementary technologies accelerate and help assure success in the drug development process Complementary technologies accelerate and help assure success in the drug development process
Certara Launches New Synchrogenix™ Writer Software to Accelerate the Regulatory Submission Process
Cloud-based and validated regulatory software automates and advances quality of patient narratives Cloud-based and validated regulatory software automates and advances quality of patient narratives
Certara Announces New Clinical Science Group and Adds Senior Scientific Experts
Multi-Disciplinary Expansion and New Appointments Grow Capacity and Capabilities Multi-Disciplinary Expansion and New Appointments Grow Capacity and Capabilities
Certara Awarded FDA Grant to Further Advance Virtual Bioequivalence Assessments of Generic Medicines Using Biosimulation
Represents Fourth FDA Grant for Simcyp MechDermA™ Model for Virtual Bioequivalence Represents Fourth FDA Grant for Simcyp MechDermA™ Model for Virtual Bioequivalence
Certara Announces Closing of its Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Pur...
PRINCETON, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it closed its public offering of 23,000,000 shares of common stoc...
Certara Stock Under Pressure On Equity Raise Of $140M At 12% Discount
Certara Inc (NASDAQ: CERT) has priced its previously announced underwritten public offering of 4.5 million shares at $31.00 per share for gross proceeds of $139.5 million. The offer price represents a d...
Certara to Participate in Upcoming Investor Conferences
PRINCETON, N.J., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in a fireside chat at the foll...